Cellectar Biosciences is a biotechnology business based in the US. Cellectar Biosciences shares (CLRB) are listed on the NASDAQ and all prices are listed in US Dollars. Cellectar Biosciences employs 15 staff and has a market cap (total outstanding shares value) of 0.00.
Finder Award
SoFi Invest
Finder Award
eToro
tastytrade
| Latest market close | $2.10 |
|---|---|
| 52-week range | $1.25 - $4.31 |
| 50-day moving average | $1.89 |
| 200-day moving average | $1.69 |
| Wall St. target price | $12.60 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-3.18 |
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an adviser or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $2.1 from 2023-09-19
| 1 week (2023-09-14) | 3.45% |
|---|---|
| 1 month (2023-08-21) | 27.27% |
| 3 months (2023-06-21) | 5.53% |
| 6 months (2023-03-21) | 37.25% |
| 1 year (2022-09-21) | -51.28% |
|---|---|
| 2 years (2021-09-21) | 118.75% |
| 3 years (2020-09-21) | 76.47% |
| 5 years (2018-09-21) | 2.7 |
| Gross profit TTM | $0 |
|---|---|
| Return on assets TTM | -124.37% |
| Return on equity TTM | -322.69% |
| Profit margin | 0% |
| Book value | $-0.19 |
| Market Capitalization | $20.5 million |
TTM: trailing 12 months
We're not expecting Cellectar Biosciences to pay a dividend over the next 12 months.
Cellectar Biosciences's shares were split on a 1:10 basis on 21 July 2022. So if you had owned 10 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Cellectar Biosciences shares – just the quantity. However, indirectly, the new 900% higher share price could have impacted the market appetite for Cellectar Biosciences shares which in turn could have impacted Cellectar Biosciences's share price.
Over the last 12 months, Cellectar Biosciences's shares have ranged in value from as little as $1.25 up to $4.3112. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Cellectar Biosciences's is 1.3351. This would suggest that Cellectar Biosciences's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Cellectar Biosciences, Inc. , a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey. .
Everything we know about the Discord IPO, plus information on how to buy in.
We’ve pulled a list together of the meme stocks being mentioned most on Reddit in the past 24 hours.
Steps to owning and managing TOTA, with 24-hour and historical pricing before you buy.
Steps to owning and managing TOT, with 24-hour and historical pricing before you buy.
Steps to owning and managing THBR, with 24-hour and historical pricing before you buy.
Steps to owning and managing SBE, with 24-hour and historical pricing before you buy.
Steps to owning and managing TEF, with 24-hour and historical pricing before you buy.
Steps to owning and managing PSACU, with 24-hour and historical pricing before you buy.
Steps to owning and managing DNK, with 24-hour and historical pricing before you buy.
Steps to owning and managing IPHA, with 24-hour and historical pricing before you buy.